Haemonetics Corp. (HAE) Misses Q4 EPS by 3c; Guides FY13 EPS Below Views
Tweet
Share
E-mailGet Alerts HAE Hot Sheet
Price: $108.40 +0.74%
EPS Growth %: +1.6%
Financial Fact:
Total operating expenses: 79.45M
Today's EPS Names:
VIVO, OCCI, ALZN, More
EPS Growth %: +1.6%
Financial Fact:
Total operating expenses: 79.45M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
Haemonetics Corp. (NYSE: HAE) reported Q4 EPS of $0.80, $0.03 worse than the analyst estimate of $0.83. Revenue for the quarter came in at $186.7 million versus the consensus estimate of $183.09 million.
Haemonetics Corp. sees FY2013 EPS of $3.30-$3.40, versus the consensus of $3.50.
For earnings history and earnings-related data on Haemonetics Corp. (HAE) click here.
Haemonetics Corp. sees FY2013 EPS of $3.30-$3.40, versus the consensus of $3.50.
For earnings history and earnings-related data on Haemonetics Corp. (HAE) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Westinghouse said to seek over $50 billion valuation in planned IPO
- Lumentum shares rise on analyst upgrades, AI demand outlook
- Arrive AI and DXC Technology partner to bring delivery tech to factories
Create E-mail Alert Related Categories
Earnings, Guidance, Hot GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
